Search Results 871-880 of 11283 for Antifungal Resistance
... resistant to ruxolitinib or 2) ineligible for ruxolitinib therapy, as determined by the treating Investigator. accelerated phase/blast phase MPN (MPN-AP/BP) ...
This oncogene creates an immunosuppressive tumor microenvironment that confers resistance to immune checkpoint inhibitor therapy, a promising treatment modality ...
Measurements of antifungal levels in corneal tissue: a simplified bioassay for amphotericin B. Williams TE. T E; O'Day DM. D M; Head WS. W S; Robinson RD. R ...
The purpose of this study is to study the length of the QTc interval in patients receiving the standard of care dose of intravenous droperidol for headache ...
Mayo Clinic discovery of breast cancer treatment resistance can lead to new hope for some featured. Mayo Clinic discovery of breast cancer treatment resistance ...
... fungal, mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any ...
Tande AJ, Stevens RW, Ilges D, Lahr BD, Challener DW. Cumulative antibiotic exposure is associated with ceftriaxone resistance among patients with urinary ...
About this study. This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior ...
This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical ...
Discovery of how MxB targets and regulates liver mitochondria. Dr. Cao has previously reported that myxovirus-resistance protein B (MxB), a member of the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.